Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 11 Prostatic Neoplasms 7 Neoplasm Metastasis 5 Ovarian Neoplasms 4 Neoplasms 4 Triple Negative Breast Neoplasms 3 Endometrial Neoplasms 3 Small Cell Lung Carcinoma 2 Fallopian Tube Neoplasms 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1

Interventions

Oxaliplatin 19 pembrolizumab 13 Fluorouracil 12 Leucovorin 11 Capecitabine 11 Paclitaxel 10 Gemcitabine 8 Docetaxel 8 zolbetuximab 6 cemiplimab 6 Cisplatin 6 Albumin-Bound Paclitaxel 6 durvalumab 5 Ramucirumab 5 Radiotherapy 5 Irinotecan 4 Cyclophosphamide 4 130-nm albumin-bound paclitaxel 4 trastuzumab deruxtecan 3 tislelizumab 3 lenvatinib 3 enzalutamide 3 darolutamide 3 Trastuzumab 3 Taxes 3 S 1 (combination) 3 Radiosurgery 3 Pemetrexed 3 Nivolumab 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × talazoparib × 1 year × Clear all

NCT06844383 2026-04-24

TALENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡